Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in Metastatic Colorectal Cancer

Collaboration to apply causal artificial intelligence and clinical trial data to identify factors that drive treatment response in patients with metastatic colorectal cancer CAMBRIDGE, Mass.– September 6, 2018 – GNS Healthcare (GNS), a leading precision medicine company, announced a cross-industry partnership with Amgen and the Alliance for Clinical Trials in Oncology (Alliance) that will apply causal […]

Amgen Ventures Invests in GNS Healthcare to Advance Applications of its REFS™ Causal Machine Learning and Simulation AI Platforms

CAMBRIDGE, Mass.– August 23, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced that it has raised an additional $6 million in equity from Amgen Ventures with participation from existing investor Alexandria Real Estate Equities. The funds will be used to further develop the company’s REFS™ causal machine learning and simulation platform and solutions […]